out individual disease from the large illness categories of our textbooks; to delineate them clinically more accurately."
Neuroglia facets of Alzheimer's disease
The most common cause of dementia in the elderly is Alzheimer's disease (AD), a progressive, multistage, ultimately fatal neurodegenerative disease with preclinical phase of a decade or longer [1] . Many features appear at different stages of AD, but the most familiar one, presenting at a late stage, is linked to the histopathological presence of extracellular deposits of fibrillar ␤-amyloid peptide (A␤), and intraneuronal accumulation of aggregates of hyper-phosphorylated Tau protein [2] . Degeneration and loss of synapses preceding neuronal death also occur [3, 4] . Neurodegeneration occurs gradually and dementia may reflect the end stage of an accumulation of pathological changes that may start to develop decade(s) before the onset of the clinical symptoms [5, 6] .
The nature of the preclinical stages of AD remains obscure. Although the current view is that neurodegeneration in AD reflects neurone-specific deficits, it is possible that preceding or concomitant changes in neuroglia may also contribute to this process [1, [6] [7] [8] [9] . Neuroglia sustain brain homoeostasis at the organ, cellular, micro-architectural, vascular, metabolic, neurotransmitter and ion levels [10] [11] [12] [13] [14] [15] and, by definition, homeostatic failure results in disease [7] . The role of neuroglia in dementia was recognised by Alois Alzheimer, who found glial cells in close contact with damaged neurones: "The glia have produced abundant fibres; concurrently many glia show large fatty sacks" [16] [17] [18] . In post-mortem tissue from patients with AD, astroglial hypertrophy (reflecting reactive astrogliosis accompanied by increased levels of glial fibrillary acidic protein (GFAP) and S100, a calcium binding protein) is often observed, particularly in astrocytes associated with senile plaques [19] [20] [21] [22] [23] . Consistent with a recent study in patients with AD [6] , distinct time-and brain-specific morphological alterations were reported in an animal mouse model of familial AD, i.e. astroglial atrophy in addition to hypertrophy was detected in certain brain areas [24] [25] [26] [27] . Astroglial asthenia preceded the appearance of senile plaques and appeared first in the entorhinal cortex, the region earliest affected by AD pathology [26] . Although the pathological developments associated with AD are of particular interest, studies in humans are difficult. Some facets of this pathology can be, to some extent, reproduced in animal models, where the evolution time of AD-like peculiarities is shorter and hence more amenable for experimentation. Thus, the aforementioned mouse models of AD offer certain opportunities for studying AD-related neuropathology. Besides mice, there are many other animal models of AD including nematodes, Drosophila flies, rabbits, canines, and non-human primates, and each model recapitulates different aspects of AD to some extent (reviewed in [28] ).
In addition to the accumulation of peptides, such as A␤, and morphological alterations of neuroglia, AD progression is also associated with brain tissue remodelling, which is often defined as neuroinflammation, because the accumulation of misfolded proteins provokes an innate immune response in the central nervous system (CNS) [1] . This response is in part associated with the A␤ deposits, because hydrophobic proteins may bind apolipoprotein E (ApoE), a major cholesterol carrier in the CNS that is synthesized and released mainly by astrocytes [29] [30] [31] . Polymorphic alleles of ApoE are the main genetic determinants of sporadic AD; individuals carrying the 4 allele are at increased risk of AD compared with those carrying the more common 3 allele, whereas the 2 allele decreases the risk of developing the disease [32] . The mechanism(s) by which the particular alleles are associated with AD are unknown, but they may be related to the capacity of the respective ApoE isoforms to prevent neuroinflammation. It has been claimed that the ApoE lipoprotein isoform function associated with neuroinflammation arises from differential binding to hydrophobic proteins, such as A␤, regulating their aggregation and clearance in the brain [33] .
ApoE-mediated effects may also be related to a general deregulation of cell metabolism and fundamental failure in neuronal-glial interaction [34] . The key mechanism of neuronal damage by reactive oxygen species and mitochondrial dysfunction in Drosophila was associated with impaired lipid metabolism in glia before or at the onset of neurodegeneration. This likely indicates impairment in lipid traffic, carried by ApoE or similar carriers, between glia and neurones, a primary defect that leads to neurodegeneration. This was further supported by experiments in which human amyloid precursor protein (APP) was expressed in neuronal cells of Drosophila, which promoted neurodegeneration; the latter could be attenuated with mimetic ApoE peptides [35] . Before neurodegeneration, lipid droplet accumulation was shown to be present in the astrocytes of an animal model of neurometabolic disorder (Leigh's disease) that affects the CNS. Ndufs −/− mutant mice exhibit mitochondrial dysfunction, which further implies impairment of brain lipid metabolism in the early stages of neurodegeneration [34] ; the Ndufs4s gene otherwise encodes a nucleus-encoded accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (complex I, or NADH:ubiquinone oxidoreductase). The ApoE-mimetic peptides derived from the receptor-binding region of ApoE were selected based on their ability to mimic the functional anti-inflammatory and neuroprotective effects of the intact ApoE protein seen in different animal models of neurological diseases [36] .
ApoE as a cholesterol-carrying protein likely contributes to cholesterol brain homeostasis. The brain is the most cholesterolrich organ in the body [37] . Due to the blood-brain barrier, there is little uptake of cholesterol by circulating lipoproteins. However, cholesterol synthesis (which occurs mainly in glia [38] ), takes place in the brain. In addition to de novo synthesis, cholesterol homeostasis in the brain also includes its enzymatic conversion to 24(S)-hydroxycholesterol [37] , which readily crosses the blood-brain barrier; this represents the major route for elimination of cholesterol from the brain. It is appealing to speculate that neurodegeneration may be initiated by defects in components of cell metabolism at a very early stage of AD.
Failure of the locus coeruleus network reset system in Alzheimer's disease
Neurones in the locus coeruleus (LC) degenerate at the early stages of AD [39] . These neurones are the primary source of noradrenaline (NA), which is known to be a generic inhibitor of neuroinflammation [40] . Thus, deficient noradrenergic innervation in the CNS may affect the progression of AD through reduced inhibition of neuroinflammation, engaging a rather diffuse innervation of the brain provided by the LC as elaborated below.
The LC localized in the brainstem contains noradrenergic neurones, which project to most, if not to all, areas in the CNS [41] ; cortical areas receive more abundant innervation [42] . The function of these diffuse projections lies in the synchronous activation of target neural ensembles, acting thus as a functional reset [43, 44] . Activation of LC projections is associated with a variety of processes, such as arousal, attention and memory, the sleep-wake cycle, behavioural flexibility, behavioural inhibition and stress, cognitive control, emotions, neuroplasticity, posture and balance [41] ; presumably these processes would be affected via activation of specific subgroups of LC projections. Simultaneous activation of all the LC projections [44] is likely reflected by gamma waves on an electroencephalogram [43] .
Noradrenaline released by the LC neurones acts through ␣-and ␤-adrenergic receptors (␣/␤-ARs), which are expressed in neurones, microglia and astrocytes. Stimulation of ␣-ARs initiates Ca 2+ signalling in astroglial cells [45] [46] [47] . Astroglial Ca 2+ signals and Ca 2+ waves propagating through astroglial syncytia were observed in vivo after stimulation of the LC in anesthetized animals [48] . Similarly, in awake animals, stimulation of LC neurones triggered (by activation of ␣ 1 -ARs) widespread astroglial Ca 2+ signals, which were generated in almost all astrocytes in the field of study [49] . This response may represent the means by which neural networks are activated coherently in space and time. In AD, however, astrocytic Ca 2+ homeostasis is altered [50, 51] , which may affect APP processing and A␤ clearance [52] . Impaired Ca 2+ signalling with subsequent glutamate toxicity may also be implicated in AD [52, 53] .
The pool of ␣-AR is activated in parallel with the ␤-AR [47] . These latter receptors are coupled to the cAMP-dependent pathway, which regulates degradation of glycogen, which otherwise acts as the energy reserve in the brain [54, 55] . Furthermore, ␤-AR/cAMP signalling controls astroglial morphological plasticity [56] . Morphological changes in astrocytes have important implications in memory formation [57] and are central for reduction of astrocytic cell oedema mediated by adrenergic receptor [58] .
Astrocytes and memory formation
Memory is defined as the process of retention and reconstruction of learned (acquired) knowledge. As recently discussed [57] , both declarative (explicit) memory for facts and events, for people, places, and objects (knowing that) and non-declarative (implicit) memory for perceptual and motor skills (knowing how) [59] , rely on similar mechanisms associated with reinforcement of synaptic transmission, which involve morphological changes at the synapses that outlast memory stabilisation [60] . While this morphology-based mechanism was suggested more than a century ago [61] , contemporary views assume that memory formation occurs in the form of molecular events at the level of an individual synaptic connection, which is termed synaptic plasticity. Synaptic changes then integrate through multiple synaptic connections involving neuronal networks, and are finally expressed at the behavioural level [62] . Memory formation is not exclusively related to neurones and their parts but also involves astrocytes [57] , which actively participate in information processing through cytosolic Ca 2+ [63, 64] and cAMP signals, as well as by elaborate secretory pathways [65, 66] although in a different time domain from neuronal communications [47, 67] . It is easy to consider interactions between astrocytes and neurones, since a single astrocyte is intimately associated with many neurones and with their synaptic contacts [68, 69] . Human hippocampal protoplasmic astrocytes are substantially larger than their rat namesakes [70] ; they are associated with ∼2 million synapses [71] , one order of magnitude higher than in rats [70] . Abundant morphological interactions of astrocytic processes with neurones are not restricted to the hippocampus; they are a widespread property of CNS tissue.
Close morphological apposition allows astrocytes to receive signals from the synaptic cleft and feed back by releasing their own signalling molecules. Release of many of these molecules occurs through a secretory pathway that uses cytoplasmic vesicles, which store chemical messengers. On stimulation, the vesicle membrane fuses with the plasmalemma, a process termed regulated exocytosis. The secretory role of neuroglia was proposed by Hans Held [72] and Jean Nageotte [73] who observed secretory granules in glial preparations. This hypothesis has been confirmed experimentally in the last two decades, and it is generally recognised that vesiclebased mechanisms participate in the heterocellular signalling that occurs at a morpho-functional unit known as the tri/multipartite synapse [74] [75] [76] . Moreover, astroglia-derived signalling molecules [65] are secreted into the extracellular space and may be transported throughout the tissue parenchyma to distant places in the CNS, likely taking advantage of the glymphatic convective system [77] . Conceivably, alterations in the shape of astrocytes may determine the long-range convective communication by glio-signalling molecules.
During implicit memory consolidation of Pavlovian threat conditioning, astrocytic processes retract from synapses in the lateral amygdala, allowing these synapses to enlarge, suggesting that contact with astroglial processes opposes synapse growth during memory consolidation [69] . In other words, if astrocytic processes enwrap synapses and the latter need to expand (or otherwise change structurally) during memory formation, astrocytes may hinder this metamorphosis, demonstrating how astrocytic structural plasticity enables morphological remodelling of synapses associated with memory formation. Under physiological conditions, including reproduction, sensory stimulation and learning, astrocytes display remarkable structural plasticity. Distal astrocytic processes can undergo morphological changes in a matter of minutes, thus modifying the geometry and diffusion properties of the extracellular space and relationships with adjacent neuronal elements, especially with synapses. This type of astroglial plasticity has important functional consequences because it modifies extracellular ionic homeostasis and neurotransmission, thus ultimately modulating neuronal function at the cellular and system levels [78] [79] [80] .
Recently it has been reported that humans with AD have increased levels of the Gs-coupled adenosine receptor A 2A in astrocytes. Conditional genetic removal of these receptors enhanced long-term memory in young and ageing mice and increased the levels of Arc (activity-regulated cytoskeleton-associated protein; also known as Arg3.1), a member of an immediate-early gene family, that is required for long-term memory (and is also expressed in astrocytes [81] ). Chemogenetic activation of astrocytic Gs-coupled signalling reduced long-term memory in mice without affecting learning. Similarly to humans with AD, ageing mice expressing human mutant APP (hAPP) showed increased levels of astrocytic A 2A receptors. Conditional genetic removal of these receptors enhanced memory in ageing hAPP mice [82] .
Dynamics of astrocyte morphology and metabolism in Alzheimer's disease
The mechanisms responsible for morphological changes in astrocytes are not known, but these likely involve LC-originated adrenergic signals and generation of cAMP [56] , which (at least in vitro) drives astrocytes into a stellate morphology with numerous processes (Fig. 1) [56, [83] [84] [85] [86] [87] [88] . This remodelling occurs within the time frame of memory consolidation (minutes to hours) and involves cytoskeletal reorganisation, including the restructuring of actin filaments, microtubules, and intermediate filaments [89, 90] . Similar morphological plasticity may take place in vivo in long-term memory formation because NA operates as a neuromodulator in Hebbian learning [91] . Under similar training conditions, changes in astrocytic shape have indeed been observed in situ [69] . Hence, if during the early stage of AD, the availability of NA becomes reduced, this may affect astroglial morphological dynamics and consequently memory formation [8] .
Alterations of astroglial morphology may have a number of consequences. Tight association between the synaptic membranes and astrocytes is considered essential for homeostatic control of the synaptic cleft, including rapid removal of glutamate [92, 93] and potassium from the extracellular space [15, 94] . Thus, retraction of astrocytic membrane from the synapse during memory formation [69] may facilitate the spillover of neurotransmitter and thus affect synaptic plasticity [95] . When these events are altered, as is likely the case during disease, homeostatic control by astrocytes is impaired. In the context of AD, astroglial cells undergo complex morphological alterations that differ between brain regions and occur at distinct stages of the disease. In the post-mortem brain, both reactive astrocytes (associated mainly with senile plaques) and degenerated, atrophic astrocytes coexist [23] . In transgenic models of AD, in PDAPP-J20 mice (carrying the Swedish and Indiana APP human mutations [96] ) and in 3xTG-AD mice (carrying mutated PS1, APP and tau genes), atrophic, degenerative forms of astroglial cells have been identified [25] . These astroglial atrophies were manifested by a decrease in the surface area and volume of astroglial GFAP-positive profiles and a reduced number of primary and secondary processes [8, 23, 26] . Astroglial atrophy had a peculiar temporal progression. It started in the entorhinal cortex (at 1 month of age), appeared somewhat later in the prefrontal cortex (between 3 and 6 months of age) and became evident in the hippocampus between 9 and 12 months of age [24, 26, 27] . In the later stages of AD, emerging extracellular depositions of A␤ trigger an astrogliotic response; although reactive hypertrophic astrocytes are mainly associated with senile plaques, astrocytes distant to the plaques remain atrophic [26] . This astroglial reactivity, however, was observed only in the hippocampus; and was absent in entorhinal and prefrontal cortices [24, 26] . Incidentally, both entorhinal and prefrontal cortices are highly vulnerable to AD pathology; this vulnerability may reflect the absence of defensive astroglial reactivity [51] . Astroglial reactivity, in turn, may be associated with differential modification of Ca 2+ signalling toolkits. A␤ induces a reactive response through release of intracellular Ca 2+ [97] and the latter is suppressed in entorhinal astrocytes when compared with hippocampal astrocytes [98] . Morphological remodelling of astrocytes may contribute to memory impairment through reduced synaptic coverage [57] and homeostatic support, which together may lead to synaptic weakness and synaptic demise, thus affecting the connectivity of neuronal networking and associated information processing. Indeed, neuronal circuits become dysfunctional in response to high A␤ levels. Recent experimental evidence obtained in mouse model studies suggests that disruption in the balance of excitation and inhibition underlies both the functional impairment of local neuronal circuits and that of large-scale networks in the amyloid-depositing brain [99] .
At the same time, astroglial deficits lead to impairment of memory formation, which is associated with morphological growth of synaptic elements together with enhanced protein synthesis and rearrangement of receptor proteins, all of which increase the energy consumption [100] . Energy substrates required for morphological synaptic plasticity are likely provided by astrocytes. With extensive end feet plastering of blood vessels, astrocytes are well positioned to take up glucose from the blood and distribute glucose or pyruvate or lactate derived from glucose to astrocytic processes surrounding synapses, possibly even through astroglial syncytia by diffusion through gap junctions [101] . Experimentally quantified diffusion of glucose within astrocytes is relatively rapid [102] and may well support glucose delivery via interconnected astrocytes in situ. Although synapses are the main energy consumers in the brain, glycogen, an important CNS energy storage system, is present mainly, if not exclusively, in astroglia. Memory consolidation in young chickens requires glycogenolysis [103, 104] . The successful consolidation of memory from short-term to longterm memory also requires neuronal NA release [105] . Therefore, it appears that NA, released from neurones, initiates astrocytic morphological changes, which involve vesicles (discussed in the next section) and activates astroglial energy metabolism. Astrocytes are also the main source of cholesterol in the CNS, which is transported to neurones by ApoE carriers in the extracellular space. While it is still unclear how NA affects lipid metabolism in astrocytes, it is safe to consider that NA signalling integrates glycolysis, morphology and function of astrocytes. Moreover, it was recently shown that NA may also prevent cell swelling in a pathological scenario [58] .
Impaired astrocytic vesicle dynamics in Alzheimer's disease
Many glio-signalling molecules that are stored in membranebound vesicles are secreted by astrocytes on the merger of the vesicle and plasma membrane [65] . In addition to molecules stored in the vesicle lumen, ion channels, membrane receptors and transporters, such as major histocompatibility complex II (MHC-II [106] ) and excitable amino acid transporter 2 (EAAT2 [107] ) are delivered to the plasma membrane by vesicle traffic [108] , which brings vesicles from the site of synthesis, deep in the cytoplasm, to the cell surface. This traffic is maintained by an elaborate system regulated by increases in [Ca 2+ ] i [108, 109] . The complexity of vesicle traffic regulation in astrocytes is characterized by two typical, yet opposing, properties of vesicles that contain peptides, such as atrial natriuretic peptide, and those that carry amino acids and are labelled by the vesicular glutamate transporter VGLUT1 [109, 110] . Namely, glutamatergic vesicle motility is accelerated by an increase in [Ca 2+ ] i [111] , whereas the same increase in [Ca 2+ ] i slows down peptidergic vesicles and endolysosomes [112] . Such regulation also applies to recycling peptidergic vesicles that have merged with the plasma membrane and subsequently re-entered the cytoplasm. The mobility of recycling peptidergic vesicles was studied in cultured astrocytes [113] and those residing in intact brain slices [114] . At rest, peptidergic vesicles moved faster and more directionally, linked to cytoskeletal elements, than after the exposure of astrocytes to ionomycin to increase [Ca 2+ ] i [113] . The effect of increased [Ca 2+ ] i was remarkable. The movement of vesicles was almost halted, with only a jitter remaining (that was associated with random diffusional movement). At least some of the peptidergic vesicles carry ATP and a similar attenuation was observed in their mobility when astrocytes were stimulated [115] .
Astrocytes from a mouse model of AD (3xTg-AD) isolated in the pre-symptomatic phase of the disease exhibit alterations in vesicle traffic (Fig. 2) . Spontaneous mobility of peptidergic and endolysosomal vesicles as well as ATP-evoked, Ca 2+ -dependent vesicle mobility were diminished in diseased astrocytes. Similar impairment of peptidergic vesicle trafficking was observed in healthy rat astrocytes transfected with familial AD-associated mutated presenilin 1 (PS1 M146V ). The stimulation-dependent peptide discharge from single vesicles was less efficient in 3xTg-AD and PS1 M146V -expressing astrocytes than in respective controls. The impaired vesicle dynamics and reduced evoked secretion of the signalling peptides may both contribute to the development of AD [50] . Although atrial natriuretic peptide-containing vesicles were examined in that study, it is likely that all peptidergic vesicles exhibit similar changes. Hence, vesicular traffic of ApoE, important for cholesterol transport between astrocytes and neurones, is also likely to be affected and may in the long term contribute to the presumed anti-inflammatory and clearing functions of ApoE in the brain. This remains to be investigated.
In AD, astrocytes associated with plaques and A␤ deposits in the hippocampus appear reactive with morphological hypertrophy and upregulated expression of intermediate filaments [116] . These reactive astrocytes may contribute to the neuroinflammatory response. After exposure to the pro-inflammatory cytokine interferon-␥ (IFN-␥), previously immunologically silent astrocytes start to express MHC-II molecules and antigens on their surface and act as nonprofessional antigen-presenting cells (APCs). Intracellular traffic of astrocytic vesicles, including endolysosomes, serves to deliver MHC-II proteins to the plasma membrane [106, 117] . The delivery of MHC-II molecules from MHC-II compartments to the cell surface of APCs is mediated via a cytoskeletal network and is most likely accomplished by the fusion of MHC-II-carrying late endolysosomes with the plasma membrane. Actin microfilaments [118] , microtubules [119, 120] , and their motor proteins [119, 121] have all been shown to mediate trafficking of MHC-II. Recently, the role of intermediate filaments in MHC-II trafficking was investi- gated in IFN-␥-activated reactive (i.e. overexpressing intermediate filament GFAP) astrocytes [106] . Upregulation of intermediate filaments allows faster and therefore more efficient delivery of MHC-II molecules to the cell surface. Reduced mobility of late endolysosomes at high [Ca 2+ ] i may increase their probability of docking to and fusion with the plasma membrane [112] . In astrocytes acting as APCs, this process may serve as an additional regulatory mechanism that controls the onset of late endolysosomal fusion and final delivery of MHC-II molecules to the cell surface [106] . Besides IFN-␥, endogenous suppressors, including NA, have been shown to regulate the expression of MHC-II molecules in astrocytes [40, 122] . Thus, when LC neurones degenerate and the amount of NA in the CNS is consequently reduced, this facilitates inflammatory processes.
Impaired astrocytic vesicle traffic is not only associated with neurodegenerative diseases, such as AD, but it is similarly affected in neurodevelopmental disorders, such as intellectual deficiency (ID) [123] . Symptoms of ID appear early in life and the disability affects about 2% of the population. Family studies have demonstrated a relatively large number of X chromosome-linked forms of ID (XLID) with an incidence of about 0.9-1.4 in 1000 males [124] . One of the first genes found to be mutated in patients with XLID is GDI1 [125] , which encodes for guanine nucleotide dissociation inhibitor (␣GDI), a protein physiologically involved in retrieving inactive GDP-bound RAB proteins from the membrane. The identification of GDI1 association with ID suggested that vesicular traffic in neural cells is an important pathway for the development of cognitive functions [126, 127] . Although the importance of ␣GDI in neuronal function has been demonstrated, it is unclear whether its role in glia vesicle trafficking contributes to the disease. The ␣GDI protein regulates the function of RAB GTPases, such as RAB 4 and RAB 5, which have been shown to regulate vesicle dynamics in astrocytes [128] , and it is likely that impaired vesicle traffic in astrocytes contributes to ID, which is linked to impaired cognitive processes involving memory formation.
Conclusions
Astrocytes provide homeostatic regulation in the CNS to support many processes, including memory formation via changes in shape, metabolic support to neurones and cell-to-cell signalling by vesicle-based mechanisms. Even very small defects in any of the processes may, over a long period of time, contribute significantly to the development of diseased states. In this article, we have highlighted multiple facets by which astrocytes contribute to AD, which also include dynamic alterations in astrocytic vesicles, which change the signalling landscape of astrocytes related to neuroinflammation, energy support and cell-to-cell communication.
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